Recombinant humanized anti-EGFR monoclonal antibody (IV) that binds EGFR’s extracellular domain to block ligand binding and receptor dimerization, suppress downstream signaling, and may engage Fc-mediated ADCC.
Humanized IgG1 monoclonal antibody against EGFR that binds the receptor’s extracellular domain to block ligand binding and receptor dimerization, inhibiting EGFR-driven signaling and tumor cell proliferation, and may induce Fc-mediated ADCC against EGFR-expressing cells.
YES
DIRECT
IgG1 anti-EGFR antibody engages Fcγ receptors on NK/effector cells to mediate ADCC against EGFR+ cells (and blocks EGFR signaling, inhibiting proliferation).
Autologous tumor-infiltrating lymphocyte (TIL) product expanded ex vivo from a patient’s resected tumor and reinfused to mediate TCR-dependent antitumor cytotoxicity.
Autologous TILs expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native TCRs (MHC-restricted) and exert cytotoxic killing of tumor cells, supported by cytokine release; typically given after lymphodepletion with IL-2 support to enhance engraftment and activity.
YES
DIRECT
Autologous TILs recognize neoantigenic peptides on HLA class I via their native TCRs and directly kill the presenting cells through perforin/granzyme cytolysis and Fas–FasL–mediated apoptosis.
Autologous tumor-infiltrating lymphocyte (TIL) product expanded ex vivo from a patient’s resected tumor and reinfused to mediate TCR-dependent antitumor cytotoxicity.
Autologous TILs expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native TCRs (MHC-restricted) and exert cytotoxic killing of tumor cells, supported by cytokine release; typically given after lymphodepletion with IL-2 support to enhance engraftment and activity.
YES
DIRECT
Autologous TILs recognize tumor-associated peptides on HLA class I via their native TCRs and directly kill target cells through perforin/granzyme- and Fas–FasL-mediated apoptosis, aided by cytokine release.
Autologous third-generation anti-CD19 CAR T-cell therapy expressing a CD19-specific scFv with CD28 and CD3ζ activation domains plus a TLR2 co-stimulatory module (1928T2z) to enhance T-cell activation, cytokine production, and persistence; targets CD19+ B cells.
Autologous third‑generation anti‑CD19 CAR T cells engineered with a CD19‑specific scFv and intracellular CD28/CD3ζ activation domains plus a TLR2 co‑stimulatory module (1928T2z). Upon binding CD19 on malignant B cells, the CAR triggers robust T‑cell activation, proliferation, cytokine production, and cytolytic killing, enhancing persistence and leading to depletion of CD19+ B cells (including normal B cells).
YES
DIRECT
Anti-CD19 CAR T cells bind CD19 on target B cells, triggering T-cell activation (CD28/CD3ζ/TLR2) and delivering cytotoxic effects via perforin/granzyme and Fas–FasL pathways, leading to direct lysis of CD19+ cells.
Autologous tumor-infiltrating lymphocyte (TIL) product expanded ex vivo from a patient’s resected tumor and reinfused to mediate TCR-dependent antitumor cytotoxicity.
Autologous TILs expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native TCRs (MHC-restricted) and exert cytotoxic killing of tumor cells, supported by cytokine release; typically given after lymphodepletion with IL-2 support to enhance engraftment and activity.
YES
DIRECT
Autologous TILs recognize patient-specific neoantigen peptides presented on HLA class II via their native TCRs and directly kill target cells through cytotoxic degranulation (perforin/granzyme) and Fas–FasL apoptosis, with supportive cytokine effects.